Eli Lilly stock jumps as drugmaker raises outlook on booming sales of diabetes and obesity treatments

Eli Lilly (LLY) stock rose 8% after raising its full-year revenue outlook to $91B-$92B, up from $85B-$87B, due to strong sales of diabetes and obesity treatments. Q3 revenue was $24.4B, exceeding estimates. Mounjaro and Zepbound generated $10.7B and $5.35B in sales, respectively. The company also plans to file for FDA approval of retatrutide in Q1 2024.

Original reporting
Published Oct 29, 2026, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eli Lilly stock jumps as drugmaker raises outlook on booming sales of diabetes and obesity treatments — source image
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The guidance lift is a fresh, material development that directly moves the stock.

02

Market read

The guidance raise is a primary catalyst for LLY and may lift health‑care sector sentiment.

03

What to watch

Potential supply chain constraints for Mounjaro and Zepbound could temper growth.

Relevance 8/10Novelty 8/10Timing: today

Background

Eli Lilly's latest guidance reflects robust sales of its GLP‑1 portfolio amid rising obesity rates.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly raised its full-year revenue outlook to $91‑$92 B, up from $85‑$87 B, prompting an 8% stock jump.

Expected impact

upward pressure as investors price in higher revenue expectations

Evidence & confidence

The new guidance is materially above prior estimates and follows a strong Q3 beat, providing a clear catalyst for continued buying.

Market effects

Boosts outlook for the broader pharma/biotech sector, especially GLP‑1 competitors.

Supports US large‑cap health‑care index performance.

Reinforces bullish sentiment on global diabetes/obesity drug markets.

Counterpoint

If upcoming regulatory scrutiny on GLP‑1 pricing intensifies, the upside could be limited.

Key entities

  • Eli Lilly

    Pharmaceutical manufacturer of Mounjaro and Zepbound.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.